Combination therapy with low dose sirolimus and tacrolimus is synergistic in preventing spontaneous and recurrent autoimmune diabetes in non-obese diabetic mice

Diabetologia

Volumn 45, Issue 2, 2002, Pages 224-230

  Shapiro, A M J ^a   Suarez Pinzon, W L ^a   Power, R ^a   Rabinovitch, A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cytokines; NOD mice; Sirolimus; Tacrolimus; Type I diabetes

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INSULIN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MESSENGER RNA; RAPAMYCIN; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AUTOIMMUNE DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETES MELLITUS; DRUG POTENTIATION; FEMALE; INCIDENCE; INSULITIS; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TH1 CELL;

ANIMALS; DIABETES MELLITUS, TYPE 1; DRUG SYNERGISM; FEMALE; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; MICE, INBRED NOD; RECURRENCE; SIROLIMUS; TACROLIMUS;

EID: 0036186826     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-001-0745-x     Document Type: Conference Paper

References (27)

1. CD3 antibody-induced dominant self tolerance in overly diabetic NOD mice
2. Reversal of established autoimmune diabetes by restoration of endogenous β cell function
3. Lessons learned from use of cyclosporine for insulin-dependent diabetes mellitus: The case for immunotherapy for insulin-dependent diabetics having residual insulin secretion
4. Rapamune (RAPA, rapamycin, sirolimus). Mechanisms of action: Immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression
5. Combined effect of rapamycin and FK506 in prolongation of small bowel graft survival in the mouse
6. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat
7. Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allografts survival in the monkey
8. Sirolimus-tacrolimus combination immunosuppression
9. Islet transplantation in seven patients with Type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen
10. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol
11. An improved method for isolation of mouse pancreatic islets
12. Prevention of recurrence of IDDM in islet-transplanted diabetic NOD mice by adjuvant Immunotherapy
13. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease
14. IFN-γ gene expression in pancreatic islet-infiltrating mononuclear cells correlates with autoimmune diabetes in nonobese diabetic mice
15. Cyclosporin A, FK506, rapamycin: The use of a quantitative analytic tool to discriminate immunosuppressive drug interactions
16. Immunopharmacology of rapamycin
17. Preventive effect of a new immunosuppressant FK-506 on insulitis and diabetes in non-obese diabetic mice
18. Effect of FK506 on spontaneous diabetes in BB rats
19. Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice
20. Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus
21. TGF-β1 alters APC preference, polarizing islet antigen responses toward a Th2 phenotype
22. Abrogation of autoimmune diabetes in nonobese diabetic mice and protection against effector lymphocytes by transgenic paracrine TGF-β1
23. TGF-β1 somatic gene therapy prevents autoimmune disease in non-obese diabetic mice
24. Testicular Sertoli cells protect islet β-cells from autoimmune destruction in NOD mice by a transforming growth factor-β1-dependent mechanism
25. + suppressor T cell completely prevents spontaneous autoimmune diabetes and recurrent diabetes in syngeneic islet-transplanted NOD mice
26. + T-cell clone in the non-obese diabetic mouse